12 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18282322 | ANTI-ALPP/ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | HECK, BRYAN WILLIAM | 1643 | Non-Final OA | Sep 15, 2023 |
| 18334680 | Glycan-Interacting Compounds and Methods of Use | BORGEEST, CHRISTINA M | 1675 | Non-Final OA | Jun 14, 2023 |
| 18030225 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | BELYAVSKYI, MICHAIL A | 1644 | Final Rejection | Apr 04, 2023 |
| 18192286 | UVEAL MELANOMA TREATMENT USING SEA-CD40 | DUNN, MCKENZIE A | 1678 | Non-Final OA | Mar 29, 2023 |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Final Rejection | Jan 25, 2023 |
| 18016648 | METHODS AND SYSTEMS FOR PRODUCING POLYPEPTIDES | TSAY, MARSHA M | 1656 | Non-Final OA | Jan 17, 2023 |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 1682 | Non-Final OA | Dec 16, 2022 |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 1642 | Non-Final OA | Nov 18, 2022 |
| 17786107 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY QUANTIFICATION OF EXCIPIENTS | VARMA, AKASH K | 1773 | Non-Final OA | Jun 16, 2022 |
| 17775492 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DONOGHUE, BRITTNEY ERIN | 1675 | Non-Final OA | May 09, 2022 |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Non-Final OA | Mar 23, 2022 |
| 16589914 | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy | JOHANSEN, PETER N. | 1644 | Final Rejection | Oct 01, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial